SR proteins regulate V₆ exon splicing of CD44 pre-mRNA

Tieng Jen Loh¹, Heeyum Moon¹, Ha Na Jang¹, Yongchao Liu¹, Namjeong Choi¹, Shengfu Shen², Darren Reece Williams¹, Da-Woon Jung¹, Xuexiu Zheng¹,* & Haihong Shen¹,*

¹School of life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, Korea, ²Willston Northampton School, Easthampton, MA 01027, USA

INTRODUCTION

In pre-mRNA splicing, introns are removed, and exons are ligated together to produce mRNA (1). Alternative splicing that produces multiple proteins from a gene plays an important role in gene expression. Alternative splicing occurs in ~95% of human genes. Thus it regulates various biological processes including cell cycle, energy transfer. Genetic diseases and cancers that are caused by abnormal RNA splicing (2-4). Both cis- and trans-acting elements are known to regulate alternative splicing. Cis-acting elements are RNA sequences that are located in exons or introns and function as splicing enhancers or inhibitors. Trans-acting elements are proteins or protein-RNA complexes that regulate alternative splicing. The best known trans-acting elements are heterogeneous nuclear ribonucleoprotein (hnRNP) and Serine-Arginine rich (SR) proteins (5, 6). The splicing-processing machinery, also known as the spliceosome, is composed of several proteins and small nuclear RNP particles (snRNPs).

The CD44 receptor directs intracellular signaling in cell growth motility through mediating adhesion and communications of cells with adjacent cells or the extracellular matrix. CD44 is a cell adhesion membrane glycoprotein. Ligands for CD44 determine CD44 functions. While growth factors modulate the growth-promotion function of CD44, hyaluronic acid mediates the tumor suppressor function of CD44 (7). CD44 pre-mRNA splicing variants. CD44 protein sizes ranged from 85 kDa (CD44s) to 250 kDa (CD44 V₆-V₁₀). V₆ exon-containing isoforms play important roles in tumor cell invasion and metastasis. The V₆ exon has been shown to be highly expressed in tumors compared with normal tissues. A CD44 V₆ exon-containing isomorph can make a complex with a tyrosine kinase receptor, Met, and hepatocyte growth factor, HGF, and then activate Met-dependent Ras signaling by the association of ezrin radixin-moesin (ERM) to CD44 on its cytoplasmic tail (12, 13).

SR proteins are a protein family that includes 13 members - SRSF1-12 and tra2β. SR proteins include a RNA recognition motif (RRM) domain and a RS domain (5). SR proteins play important roles in alternative and constitutive splicing. In constitutive splicing, SR proteins are known to promote the binding of U1 snRNP to 5’ splice-site and the binding of U2 snRNP binding to a branch-point in spliceosome assembly (14, 15). In alternative splicing, SR proteins are shown to antagonize hnRNP functions (16). SR proteins could promote exon inclusion or skipping through interactions with exons or introns. In addition to playing different roles in RNA splicing. SR proteins also function in transcription elongation, RNA
SR proteins regulate V6 exon splicing of CD44 pre-mRNA

Tieng Jen Loh, et al.

Fig. 1. SR proteins regulate V6 exon splicing of CD44 pre-mRNA.

(A) pFlare-V6 minigene is shown. V6 exon is shown with a black box, β-globin and GFP/RFP exons are shown with white/gray boxes. Introns that flank V6 are shown with thicker lines, introns of β-globin and GFP are shown with thinner lines. (B) RT-PCR analysis using RNAs from pFlare-V6 MCF7 cells treated with pcDNA3.1+ or SRSF2 or SRSF6 or SRSF4. Quantitation results by Image J from three independent experiments are shown at the bottom. The significant change was evaluated by Student’s t-test. The error bars represent the standard deviation of the repeats.

Fig. 2. SRSF1, SRSF6, and SRSF9 inhibit V6 exon splicing. RT-PCR analysis using RNAs from pFlare-V6 MCF7 cells treated with pcDNA3.1+ or SRSF1 or SRSF6 or SRSF9. Quantitation results by Image J from three or more independent experiments are shown at the bottom. The significant change was evaluated by Student’s t-test. Results are expressed as percentages of ratio skipping V6/total. The error bars represent the standard deviation of the repeats.
level (~44%, ~36% and ~46% independently). Therefore, we conclude that SRSF1, SRSF6, and SRSF9 inhibit V6 exon splicing.

Using a primer set that base pairs with constitutive exons could not detect the induction of the various exon-included isoforms obtained by reducing SR protein expression

We next wondered whether reduced expression of SR proteins could induce alteration of endogenous CD44 splicing. To address this question, we treated MCF7 cells using lentivirus-mediated shRNA and then extracted the RNA from cells. The standard primers that base pair with constitutive C5 and C6 exons were used to detect both the isoform that includes only constitutive exons (C) and the isoforms that include any variant isoform (V) (lower panel, Fig. 3). Consistent with the previously reported results (19, 20), RT-PCR results for CD44 splicing using these primers show that the C isoform was predominantly detected, whereas V isoforms were not detected (lane 1, Fig. 3). Moreover, non-silencing (NS) shRNA treatment did not induce any alteration of CD44 splicing (lane 2), suggesting that the NS shRNA can be used as a negative control. The results using shRNAs that target different SR proteins suggest that reduced expression of SRSF1, SRSF2, SRSF3, SRSF4, and SRSF9 did not induce production of any V isoform (lanes 3-7). The results are consistent with the conclusion that SRSF3 and SRSF4 did not affect CD44 splicing, but not with the conclusion that SRSF1, SRSF2, and SRSF9 regulate V6 exon splicing.

Using V6 exon-specific primer could detect the induction of various exon-included isoforms by reduced SRSF2

As the primers could not detect various isoform containing isoforms, we determined to use one primer that base pairs with V6 exon and the other primer that base pairs with the C6 exon (lower panel, Fig. 4). The primers could detect V6-10 exon combinations, but not V2-V5. The Fig. 4 results show that the isoform that includes only V6 isoform among V6-10 was dominantly detected (V6, lane 1). In addition, an isoform that includes V6, V7, V8, and V10 (V6,10) and an isoform that includes V6, V7, V8, and V10 (V6,8,10) were produced in less significant levels. We next asked whether reduced expression of SR proteins affects the expression of these CD44 isoforms. Fig. 4 results demonstrate that reduced expression of SRSF3 and SRSF1 caused a decrease of V6,10 and V6,8,10 isoforms (lanes 2 and 6). Moreover, reduced SRSF9 and SRSF4 expression did not induce a significant change of CD44 isoforms. Most significantly, reduced expression of SRSF2 induced decreased expression of V6 but increased expression of both V6,10 and V6,8,10 expression. Our results suggest that SRSF2 is a key player in CD44 V6 splicing.

DISCUSSION

CD44 pre-mRNA splicing is one of the most complicated splicing events in human genes. The CD44 pre-mRNA includes 10 constant exons, exons 1-5 (C1-C5) and 16-20 (C6-C10), and 10 various exons, exons 6-15 (V1-V10) (18-20). Here, we studied the function of SR proteins on V6 exon splicing of CD44 pre-mRNA. First, in the overexpression of SR proteins into the pFlare-V6 minigene-harboring MCF7 stable cell line, we demonstrated that SRSF1, SRSF6, and SRSF9 (but not SRSF3 and SRSF4) inhibit V6 exon splicing. Next, we
analyzed the SR proteins function by reducing their expression levels through shRNA treatment. We found that, by using a primer set that base pairs with the constitutive exons of CD44 pre-mRNA, the changes of alternative splicing by SR proteins were not detectable. However, Using the primer that base pairs with the V6 exon, we show that SRSF2-targeting shRNA decreased the V6 isoform significantly, and also increased V6-10 and V6B-10 isoforms. Our results indicate that CD44 V6 splicing is regulated by SR proteins.

SR proteins have been known to function through binding to the enhancer to promote spliceosome assembly (21-23). Recently it was also reported that SR proteins can either promote or inhibit exon inclusion (24-26). In addition, using tethered SR proteins, it was demonstrated that splicing activation and repression by SR proteins depends on the location of their binding (27). Our results demonstrate that although all of the SR proteins we analyzed could potentially interact with V6 exon and flanking introns, only some of them could inhibit V6 splicing. Furthermore, the locations of SR protein binding did not affect their functions. The results can be explained that various potential binding locations of SR proteins on V6 exon and flanking introns could possibly function through combinatorial or synergistically. How these combination or synergistic effects regulate alternative splicing has not been well understood. One of our most striking results is that reduced SRSF2 expression could induce various V6 exon-containing isoforms. Further study is need to determine the protein functions of these mRNA isoforms.

Our results indicate that the SR proteins, whose overexpression showed inhibitory effects on V6 splicing, did not demonstrate significant effects as their expressions were reduced. This kind of quantitative differences have been reported in other studies (19, 20, 28). Another possibility is the assay systems in our experiments: While overexpression experiments were performed using a minigene-harboring stable cell line, shRNA treatments were performed by analyzing endogenous CD44 splicing. Another reason for differing results between the assay systems could be attributed to varying primer sequences used for analyzing V6 splicing of CD44 pre-mRNA. The results indicate that various exons in CD44 pre-mRNA should be detected using a primer that base pairs with itself.

MATERIALS AND METHODS

Cell culture
MCF7 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM; Hyclone) supplemented with antibiotics (100 U/ml penicillin G and 100 µg/ml streptomycin) and 10% of Fetal Bovine Serum (FBS; Hyclone) under humidified 5% CO2 conditions at 37°C. The stable pFlareV6, stable cell was obtained as previously described (18). Different SR proteins plasmids were transfected into the stable cells using polyethyleneimine (PEI) Reagent according to the manufacturer’s protocol.

RT-PCR
Total RNAs were extracted using RiboEx reagent (GeneAll) following manufacturer’s protocol. RT-PCR was conducted as previously described (19, 20). For the endogenous CD44 pre-mRNA splicing, RT-PCR was conducted as previously described (29). A specific primer, CD44RT (5'-ATG CAA ACT ACC CCA GCA AC-3'), Exon C7 Fwd (5'-TTT GAT GAA CTT CAG G-3'), Exon C7 Rev (5'-TTT GCT AGG CAA CTC CTA GTA GT-3'), Exon C7 Rev (5'-TTT GCC CCA CCT TCT TGA CTC C-3'), CD44 splicing [For (5'-AAC ACA TCT ACC CCA GCA AC-3'), Exon C7 Rev (5'-TTT GCC CCA CCT TCT TGA CTC C-3'), V6 splicing [Fwd (5'-TCC AGG CAA CTC GTA GT-3'), Exon C7 Rev (5'-TTT GCC CCA CCT TCT TGA CTC C-3')]. The endogenous RT-PCR products were confirmed by sequencing.

shRNA treatment
The shRNA lentivirus was prepared using different SR protein shRNA plasmid as previous described (19, 20). Knockdown of SR proteins was performed by treating cells with the virus for 72 h.

ACKNOWLEDGEMENTS
This work was supported by the NRF-2015R1A2A1A15054247 grant to Haichong Shen, the NRF-2016R1A2B1007135 grant to Xuexiu Zheng and Cell Logistics Research center (2016R1A5A1007318) funded by the National Research Foundation (NRF) of Korea, and an integrative aging research grant at the Gwangju Institute of Science and Technology (GIST).

REFERENCES
1. Green MR (1986) Pre-mrna splicing. Annu Rev Genet 20, 671-708
2. David CJ and Manley JL (2010) Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged. Genes Dev 24, 2343-2364
3. Cooper TA, Wan L and Dreyfuss G (2009) Rna and disease. Cell 136, 777-793
4. Kim E, Goren A and Ast G (2008) Insights into the connection between cancer and alternative splicing. Trends Genet 24, 7-10
5. Busch A and Hirtel K (2012) Evolution of sr protein and hnrnp splicing regulatory factors. Wiley Interdiscip Rev RNA 3, 1-12
6. Han SP, Tang YH and Smith R (2010) Functional diversity of the hnrnps: Past, present and perspectives. Biochem J 430, 379-392
7. Herrlich P, Morrison H, Sleeman J et al (2000) Cd44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci 910, 106-118; discussion 118-120
8. Scretalon GR, Bell MV, Bell JJ and Jackson DG (1993) The identification of a new alternative exon with highly
SR proteins regulate V6 exon splicing of CD44 pre-mRNA
Tieng Jen Loh, et al.

restricted tissue expression in transcripts encoding the mouse pgp-1 (cd44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat. J Biol Chem 268, 12235-12238

9. Bennett KL, Jackson DG, Simon JC et al (1995) Cd44 isoforms containing exon v3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 128, 687-698

10. Orian-Rousseau V and Ponta H (2008) Adhesion proteins meet receptors: A common theme? Adv Cancer Res 101, 63-92

11. Tremmel M, Matzke A, Albrecht I et al (2009) A cd44v6 peptide reveals a role of cd44 in vegfr-2 signaling and angiogenesis. Blood 114, 5236-5244

12. Orian-Rousseau V, Chen I, Sleeman JP, Herrlich P and Ponta H (2002) Cd44 is required for two consecutive steps in hgf/c-met signaling. Genes Dev 16, 3074-3086

13. Legg JW and Isacke CM (1998) Identification and functional analysis of the ezrin-binding site in the hyaluronan receptor, cd44. Curr Biol 8, 705-708

14. Boukis LA, Liu N, Furuyama S and Bruzik JP (2004) Ser/arg-rich protein-mediated communication between u1 and u2 small nuclear ribonucleoprotein particles. J Biol Chem 279, 29647-29653

15. Shao W, Kim HS, Cao Y, Xu YZ and Query CC (2012) A u1-u2 snrnp interaction network during intron definition. Mol Cell Biol 32, 470-478

16. Bai Y, Lee D, Yu T and Chasin LA (1999) Control of 3’ splice site choice in vivo by asf/sf2 and hnrrnp a1. Nucleic Acids Res 27, 1126-1134

17. Zhong XY, Wang P, Han J, Rosenfeld MG and Fu XD (2009) Sr proteins in vertical integration of gene expression from transcription to RNA processing to translation. Mol Cell 35, 1-10

18. Loh TJ, Moon H, Cho S et al (2014) Sc35 promotes splicing of the c5-v6-c6 isoform of cd44 pre-mRNA. Oncol Rep 31, 273-279

19. Mi Y, Zhang C, Bu Y et al (2015) DEPDC1 is a novel cell cycle related gene that regulates mitotic progression. BMB Rep 48, 413-418

20. Han A, Chae YC, Park JW, Kim KB, Kim JY, Seo SB (2015) Transcriptional repression of ANGPT1 by histone H3K9 demethylase KDM3B. BMB Rep 48, 401-406

21. Sun Q, Mayeda A, Hampson RK, Krainer AR and Rottman FM (1993) General splicing factor sf2/ASF promotes alternative splicing by binding to an exonic splicing enhancer. Genes Dev 7, 2598-2608

22. Chandler SD, Mayeda A, Yeakley JM, Krainer AR and Fu XD (1997) Rna splicing specificity determined by the coordinated action of RNA recognition motifs in sr proteins. Proc Natl Acad Sci U S A 94, 3596-3601

23. Anko ML, Morales L, Henry I, Beyer A and Neugebauer KM (2010) Global analysis reveals sp20- and sp75-specific mrnps in cycling and neural cells. Nat Struct Mol Biol 17, 962-970

24. Pandit S, Zhou Y, Shiue L et al (2013) Genome-wide analysis reveals sr protein cooperation and competition in regulated splicing. Mol Cell 50, 223-235

25. Simard MJ and Chabot B (2002) Srp30c is a repressor of 3’ splice site utilization. Mol Cell Biol 22, 4001-4010

26. Han J, Ding JH, Byeoon CW et al (2011) Sr proteins induce alternative exon skipping through their activities on the flanking constitutive exons. Mol Cell Biol 31, 793-802

27. Erkelenz S, Mueller WF, Evans MS et al (2013) Position-dependent splicing activation and repression by sr and hnrrnp proteins rely on common mechanisms. RNA 19, 96-102

28. Bielli P, Bordi M, Di Biasio V and Sette C (2014) Regulation of bcl-x splicing reveals a role for the polypyrimidine tract binding protein (pbr1/hnrrnp i) in alternative 5’ splice site selection. Nucleic Acids Res 42, 12070-12081

29. van Weering DH, Baas PD and Bos JL (1993) A PCR-based method for the analysis of human cd44 splice products. PCR Methods Appl 3, 100-106